



## Biocon Biologics in Mexico: Factsheet

**Biocon Biologics is a leading global biosimilars company committed to addressing patients' needs for cost-effective, high-quality biosimilars.**

### VISION

To be a global leader in biologics, delivering affordable access to innovative and inclusive healthcare solutions, transforming patients' lives.

### VALUES

- Innovation & differentiation
- Quality through compliance & best practices
- Integrity and ethical behaviour
- Collaboration, teamwork and mutual respect
- Performance-driven culture

### Company Profile

**Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class 'lab to market' capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.**

In the Latin America (LATAM) region, Biocon Biologics is making a significant impact on patients' lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 8 commercialized biosimilars.

Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the LATAM region through its state-of-the-art manufacturing

infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.

In Mexico, we work with our local partners, Laboratios PISA and Synthon Mexico. Biocon Biologics is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease through three of its products for the benefit of patients and improving healthcare outcomes in Mexico.


Headquartered in Bengaluru, India, Biocon Biologics has a longstanding presence in the biosimilars industry, having invested over \$1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner Viatris has further strengthened Biocon Biologics' commercial presence in Mexico. As a trusted and reliable company, Biocon Biologics is poised to grow and consolidate its leadership in biosimilars in Mexico, making a meaningful impact on patients' lives.

## The Biocon Biologics Advantage

- **PATIENT-CENTRICITY:** Committed to expand patient reach and generate significant saving for patients, payers, and healthcare systems.
- **LAB-TO-MARKET EXPERTISE:** Fully integrated from biosimilars development to manufacturing, distribution and commercialization.
- **LEGACY OF SUCCESS:** Cutting-edge scientific and technological capabilities leading to many 'firsts' in the industry - first to receive approvals in U.S. for biosimilar Trastuzumab, biosimilar Pegfilgrastim and interchangeable biosimilar Insulin Glargine.
- **UNIQUE PORTFOLIO:** Comprehensive and differentiated portfolio of biosimilars, including insulins, monoclonal antibodies, and recombinant proteins.
- **GLOBAL SCALE PRODUCTION:** Operates 3 large scale, globally compliant biosimilars manufacturing facilities; Among the Top 15\* companies globally in terms of biomanufacturing capacity.
- **WORLDWIDE COMMERCIAL FOOTPRINT:** Commercialized products in 120+ countries through a combination of direct presence, strategic partnerships and distributors.
- **PROVEN TRACK RECORD:** 80+ cGMP approvals obtained from international regulatory agencies.

\*19th Annual Report of BioPlan Associates

## QUICK FACTS



## 4A Model of Enabling Health Equity

- **Affordability:** Rationalizing treatment costs while improving healthcare outcomes.
- **Availability:** Ensuring reliable product supplies across Advanced and Emerging Markets.
- **Accessibility:** Maximizing patient reach through country-specific self and partner-led commercial models.
- **Assurance:** Establishing a trustworthy brand that stands for the highest global quality.

## Our Products in Mexico

Brand Name	Molecule
Krabeva	Bevacizumab*
Basalog	Insulin Glargine**
Insugen	Rh-Insulin**

\* Commercialized by our partner Synthon Mexico in Mexico;

\*\* Commercialized by our partner Laboratios PISA in Mexico.

## Global Portfolio

Trastuzumab	Insulin Glargine
Bevacizumab	Insulin Aspart
Pegfilgrastim	Adalimumab
rh-Insulin	Etanercept
Ustekinumab	

## Biocon Biologics in Mexico

### Business Partnership

**Marcelo Dos Santos**  
Commercial Head, LATAM Region  
Email: marcelo.dossantos@biocon.com

**Susheel Umesh**  
Chief Commercial Officer,  
Emerging Markets  
Email: susheel.umesh@biocon.com

### Media

**Seema Ahuja**  
Global Head of Corporate Brand  
& Head of Communications – EMs  
Email: seema.ahuja@biocon.com

### Adverse Events

**Email:**  
DrugSafety@biocon.com

Last updated: March, 2025

For more information:  
Biocon Biologics Corporate Factsheet  
Website: <https://www.bioconbiologics.com>

